Medical Advocates
HIV Infection/Disease
  Lipoatrophy  
General Reports
 Facial Lipoatrophy
Clinical Management
Mitochondrial Disorders




 

 
HIV Metabolic Main Page   Main New/Newsworthy Home Page  
Last Update: July 04, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
       
          Journal Papers, Abstracts, and Commentaries
 
 
Impact of lipoatrophy on patient-reported outcomes in antiretroviral-experienced patients.
Doward LC, Dietz B, Wilburn J,  
AIDS Read. 2008 May;18(5):242-6, 252-6,
 Abstract
 
Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during
antiretroviral therapy: a case-control study.
Wunder DM, Fux CA, Bersinger NA, et al
HIV Med. 2008 May 3
 Abstract
 
Association of APOC3 Polymorphisms with Both Dyslipidemia and Lipoatrophy in
HAART-Receiving Patients.
 Bonnet E, Bernard J, Fauvel J, Massip P
 AIDS Res Hum Retroviruses. 2008 Feb 1
Abstract
 
Antiretroviral Therapies Associated with Lipoatrophy in HIV-Infected Women.
Tien PC, Barron Y, Justman JE, et al
AIDS Patient Care STDS. 2007 May;21(5):297-305
 Abstract
 
Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years
compared with the background population.
 Hansen A, Lindegaard B, Obel N, et al
HIV Med. 2006 Jan;7(1):38-45
 Abstract
 
FULL-TEXT ARTICLE
 Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for
HIV1 infection: case report.
Parruti G, Marani Toro G.
BMC Infect Dis. 2005 Oct 3;5(1):80
 Paper
 
The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with
lipodystrophy.
 Shah M, Tierney K, Adams-Huet B, et al
HIV Med. 2005 Jul;6(4):291-8.
 Abstract
 
Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less
lipoatrophic but more hypertensive.
Bergersen B, Sandvik L, Ellingsen I, Bruun J.
HIV Med. 2005 Jul;6(4):260-7.
Abstract
 
Host factors may be more important than choice of antiretrovirals in the
development of lipoatrophy.
McComsey G, Maa JF.
AIDS Read. 2003 Nov;13(11):539-42, 559.
Abstract

Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are
associated with serum concentrations of leptin.
Nagy GS, Tsiodras S, Martin LD, et al.
Clin Infect Dis 2003 Mar 15;36(6):795-802
 Abstract

Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory
HIV-1-Infected Patients.
Lichtenstein KA, Delaney KM, Armon C, et al.
J Acquir Immune Defic Syndr 2003 Jan 1;32(1):48-56
 Abstract
 

  
              Conference Reports, Abstracts, and Posters
 
 
POSTER
How Much Fat Loss Is Needed for Lipoatrophy to Become Clinically Evident?
D Podzamczer, E Ferrer, E Martinez, et al
(15 CROI)
PDF Poster   Abstract
 
POSTER
Lipoatrophy and Lipohypertrophy Are Independently Associated with Hypertension:
The Effect of Lipoatrophy but not Lipohypertrophy on Hypertension Is Independent
of Obesity
H Crane, C Grunfeld, R Harrington, M Kitahat
(15 CROI)
 PDF Poster   Abstract
 
Improvements in Hepatic and Adipocyte Insulin Sensitivity, Dyslipidemia, and Visceral Fat
during Leptin Treatment in HIV-infected Men with Lipoatrophy and Hypoleptinemia
 K Mulligan, H Khatami, J M Schwarz, et al
 (14 CROI)
 Abstract
 
FASl-670 and APOC3 Polymorphisms as Predictors of Lipoatrophy in Patients
Receiving ART
A Cossarizza, A Riva, B Zanone Poma, et al 
(13 CROI)
Abstract
 
Changes in Androgens and Gonadotropin during HAART and Their Association
with Development of Lipoatrophy in HIV-infected Men
 D Wunder, N Bersinger, R Weber, et al
(12 CROI)
 Abstract
 
Pronounced lipoatrophy without truncal fat accumulation in patients on long term
HAART compared with background population
AE Hansen, B Lindegaard, O Andersen, et al
 (15IAC)
 Abstract
 
Correlates of risk of concomitant presentation of lipoatrophy, lipohypertrophy and
hypertriglyceridemia in HIV-positive patients on first-line antiretroviral therapy
M Galli, A Cozzi-Lepri, A  Ridolfo, et al
 (15IAC)
 Abstract
 
Baseline Triglyceride Levels Predict Development of Lipoatrophy in Patients
Treated with Stavudine Extended-release/Prolonged-release Capsules or Stavudine
Immediate-release
 M Noor, C Dezii, C McLaren, et al.
 (11 CROI)
 Abstract
 
Incidence and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory
HIV-1-Infected Patients
 K Lichtenstein, K Delaney, D Ward, et al
 (9 CROI)
 Abstract
 

Clinical Management
       
          Journal Papers, Abstracts, and Commentaries
 
 
A Randomized, Placebo-Controlled Trial of Rosiglitazone for HIV-Related Lipoatrophy.
Cavalcanti RB, Raboud J, Shen S, et al
J Infect Dis. 2007 Jun 15;195(12):1754-61.
 Abstract

Plastic Surgical Approaches for HIV-associated Lipoatrophy.
 Moyle GJ. 
Curr HIV/AIDS Rep. 2005 Aug;2(3):127-31.
Abstract

Therapeutic approaches to combating lipoatrophy: do they work?
 Martin A, Mallon PW. 
J Antimicrob Chemother. 2005 Mar 10;
 Abstract
 
Interventions for managing antiretroviral therapy-associated lipoatrophy.
 Sutinen J. 
Curr Opin Infect Dis. 2005 Feb;18(1):25-33.
 Abstract
 
Improvement in lipoatrophy associated with highly active antiretroviral therapy
in human immunodeficiency virus-infected patients switched from stavudine
to abacavir or zidovudine: the results of the TARHEEL study.
 McComsey GA, Ward DJ, Hessenthaler SM, et al.  
 Clin Infect Dis. 2004 Jan 15;38(2):263-70
 Abstract
 
Prospective evaluation of the effects of antiretroviral therapy on body composition in
HIV-1-infected men starting therapy.
 Mallon PW, Miller J, Cooper DA, Carr A.
 AIDS 2003 May 2;17(7):971-9
 Abstract
 
Long-term metabolic consequences of switching from protease inhibitors to
efavirenz in therapy for human immunodeficiency virus -infected patients with lipoatrophy.
 Estrada V, De Villar NG, Larrad MT
Clin Infect Dis 2002 Jul 1;35(1):69-76
 Abstract
 
              Conference Reports, Abstracts, and Posters
 
  Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized Double-Blind Placebo-
Controlled Trial (ANRS 113) with 130 patients
L Slama, E Lanoy, M A Valentin,  et al
(13 CROI)
 Abstract
 
Toxicity and Efficacy of 3TC/EFV Associated with Stavudine or Abacavir in
Antiretroviral-naive ve Patients: 48-week Results of a Randomized Open and
Multicenter Trial (ABCDE Study)
 D Podzamczer, E Ferrer, P Sanchez, et  al
(11 CROI)
 Abstract

Mitochondrial Disorders
       
          Journal Papers, Abstracts, and Commentaries
 
 

Mitochondrial Abnormalities in HIV-Infected Lipoatrophic Patients Treated With
Antiretroviral Agents.
 Chapplain JM, Beillot J, Begue JM, et al 
J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1477-1488.
 Abstract

HIV Metabolic Main Page   Main New/Newsworthy Home Page  

Lipoatrophy